Effectiveness	O
of	O
aprepitant	B:C1176306
in	O
addition	O
to	O
ondansetron	O
in	O
the	O
prevention	O
of	O
nausea	O
and	O
vomiting	O
caused	O
by	O
fractionated	O
radiotherapy	I:C1997554
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
AVERT	O
)	O
.	O

Effectiveness	O
of	O
aprepitant	O
in	O
addition	O
to	O
ondansetron	B:C0061851
in	O
the	O
prevention	O
of	O
nausea	O
and	O
vomiting	O
caused	O
by	O
fractionated	O
radiotherapy	I:C1997554
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
AVERT	O
)	O
.	O

Effectiveness	O
of	O
aprepitant	O
in	O
addition	O
to	O
ondansetron	O
in	O
the	O
prevention	O
of	O
nausea	B:C0027497
and	O
vomiting	O
caused	O
by	O
fractionated	O
radiotherapy	I:C1997554
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
AVERT	O
)	O
.	O

Effectiveness	O
of	O
aprepitant	O
in	O
addition	O
to	O
ondansetron	O
in	O
the	O
prevention	O
of	O
nausea	O
and	O
vomiting	B:C0042963
caused	O
by	O
fractionated	O
radiotherapy	I:C1997554
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
AVERT	O
)	O
.	O

Effectiveness	O
of	O
aprepitant	O
in	O
addition	O
to	O
ondansetron	O
in	O
the	O
prevention	O
of	O
nausea	O
and	O
vomiting	O
caused	O
by	O
fractionated	B:C1997554
radiotherapy	I:C1997554
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
AVERT	O
)	O
.	O

Effectiveness	O
of	O
aprepitant	O
in	O
addition	O
to	O
ondansetron	O
in	O
the	O
prevention	O
of	O
nausea	O
and	O
vomiting	O
caused	O
by	O
fractionated	O
radiotherapy	I:C1997554
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
AVERT	B:C1997554
)	O
.	O

Despite	O
a	O
lower	O
risk	O
of	O
nausea	B:C0027497
and	O
vomiting	O
in	O
patients	O
receiving	O
radiotherapy	O
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
UA	O
-	I:C1997554
RINV	I:C1997554
)	O
with	O
prophylactic	O
5	I:C2347899
-	I:C2347899
HT3	I:C2347899
antagonist	I:C2347899
therapy	I:C2347899
,	O
patients	O
can	O
still	O
experience	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

Despite	O
a	O
lower	O
risk	O
of	O
nausea	O
and	O
vomiting	B:C0042963
in	O
patients	O
receiving	O
radiotherapy	O
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
UA	O
-	I:C1997554
RINV	I:C1997554
)	O
with	O
prophylactic	O
5	I:C2347899
-	I:C2347899
HT3	I:C2347899
antagonist	I:C2347899
therapy	I:C2347899
,	O
patients	O
can	O
still	O
experience	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

Despite	O
a	O
lower	O
risk	O
of	O
nausea	O
and	O
vomiting	O
in	O
patients	O
receiving	O
radiotherapy	B:C1997554
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
UA	O
-	I:C1997554
RINV	I:C1997554
)	O
with	O
prophylactic	O
5	I:C2347899
-	I:C2347899
HT3	I:C2347899
antagonist	I:C2347899
therapy	I:C2347899
,	O
patients	O
can	O
still	O
experience	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

Despite	O
a	O
lower	O
risk	O
of	O
nausea	O
and	O
vomiting	O
in	O
patients	O
receiving	O
radiotherapy	O
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
UA	B:C1997554
-	I:C1997554
RINV	I:C1997554
)	O
with	O
prophylactic	O
5	I:C2347899
-	I:C2347899
HT3	I:C2347899
antagonist	I:C2347899
therapy	I:C2347899
,	O
patients	O
can	O
still	O
experience	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

Despite	O
a	O
lower	O
risk	O
of	O
nausea	O
and	O
vomiting	O
in	O
patients	O
receiving	O
radiotherapy	O
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
UA	O
-	I:C1997554
RINV	I:C1997554
)	O
with	O
prophylactic	B:C2347899
5	I:C2347899
-	I:C2347899
HT3	I:C2347899
antagonist	I:C2347899
therapy	I:C2347899
,	O
patients	O
can	O
still	O
experience	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

Despite	O
a	O
lower	O
risk	O
of	O
nausea	O
and	O
vomiting	O
in	O
patients	O
receiving	O
radiotherapy	O
to	I:C1997554
the	I:C1997554
upper	I:C1997554
abdomen	I:C1997554
(	O
UA	O
-	I:C1997554
RINV	I:C1997554
)	O
with	O
prophylactic	O
5	I:C2347899
-	I:C2347899
HT3	I:C2347899
antagonist	I:C2347899
therapy	I:C2347899
,	O
patients	O
can	O
still	O
experience	O
UA	B:C1997554
-	I:C1997554
RINV	I:C1997554
.	O

The	O
aim	O
of	O
this	O
multicenter	B:C1096776
phase	I:C1096776
II	I:C1096776
study	I:C1096776
was	O
to	O
assess	O
effectiveness	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
protracted	O
dual	I:C0164209
NK1	I:C0164209
-	I:C0164209
receptor	I:C0164209
and	O
5	O
-	I:C0360055
HT3	I:C0360055
antagonist	I:C0360055
prophylaxis	O
against	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

The	O
aim	O
of	O
this	O
multicenter	O
phase	I:C1096776
II	I:C1096776
study	I:C1096776
was	O
to	O
assess	O
effectiveness	O
,	O
safety	O
,	O
and	O
tolerability	B:C3274448
of	O
protracted	O
dual	I:C0164209
NK1	I:C0164209
-	I:C0164209
receptor	I:C0164209
and	O
5	O
-	I:C0360055
HT3	I:C0360055
antagonist	I:C0360055
prophylaxis	O
against	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

The	O
aim	O
of	O
this	O
multicenter	O
phase	I:C1096776
II	I:C1096776
study	I:C1096776
was	O
to	O
assess	O
effectiveness	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
protracted	B:C0164209
dual	I:C0164209
NK1	I:C0164209
-	I:C0164209
receptor	I:C0164209
and	O
5	O
-	I:C0360055
HT3	I:C0360055
antagonist	I:C0360055
prophylaxis	O
against	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

The	O
aim	O
of	O
this	O
multicenter	O
phase	I:C1096776
II	I:C1096776
study	I:C1096776
was	O
to	O
assess	O
effectiveness	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
protracted	O
dual	I:C0164209
NK1	I:C0164209
-	I:C0164209
receptor	I:C0164209
and	O
5	B:C0360055
-	I:C0360055
HT3	I:C0360055
antagonist	I:C0360055
prophylaxis	O
against	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

The	O
aim	O
of	O
this	O
multicenter	O
phase	I:C1096776
II	I:C1096776
study	I:C1096776
was	O
to	O
assess	O
effectiveness	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
protracted	O
dual	I:C0164209
NK1	I:C0164209
-	I:C0164209
receptor	I:C0164209
and	O
5	O
-	I:C0360055
HT3	I:C0360055
antagonist	I:C0360055
prophylaxis	B:C0199176
against	O
UA	O
-	I:C1997554
RINV	I:C1997554
.	O

The	O
aim	O
of	O
this	O
multicenter	O
phase	I:C1096776
II	I:C1096776
study	I:C1096776
was	O
to	O
assess	O
effectiveness	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
protracted	O
dual	I:C0164209
NK1	I:C0164209
-	I:C0164209
receptor	I:C0164209
and	O
5	O
-	I:C0360055
HT3	I:C0360055
antagonist	I:C0360055
prophylaxis	O
against	O
UA	B:C1997554
-	I:C1997554
RINV	I:C1997554
.	O

Patients	O
receiving	O
fractionated	B:C1522449
radiotherapy	I:C1522449
with	O
radiosensitizing	O
chemotherapy	O
received	O
oral	O
ondansetron	O
8	O
mg	O
po	O
q12	O
h	O
and	O
aprepitant	O
125/80/80	O
mg	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
Friday	O
schedules	O
throughout	O
radiotherapy	O
.	O

Patients	O
receiving	O
fractionated	O
radiotherapy	I:C1522449
with	O
radiosensitizing	B:C0436310
chemotherapy	O
received	O
oral	O
ondansetron	O
8	O
mg	O
po	O
q12	O
h	O
and	O
aprepitant	O
125/80/80	O
mg	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
Friday	O
schedules	O
throughout	O
radiotherapy	O
.	O

Patients	O
receiving	O
fractionated	O
radiotherapy	I:C1522449
with	O
radiosensitizing	O
chemotherapy	B:C3665472
received	O
oral	O
ondansetron	O
8	O
mg	O
po	O
q12	O
h	O
and	O
aprepitant	O
125/80/80	O
mg	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
Friday	O
schedules	O
throughout	O
radiotherapy	O
.	O

Patients	O
receiving	O
fractionated	O
radiotherapy	I:C1522449
with	O
radiosensitizing	O
chemotherapy	O
received	O
oral	B:C0442027
ondansetron	O
8	O
mg	O
po	O
q12	O
h	O
and	O
aprepitant	O
125/80/80	O
mg	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
Friday	O
schedules	O
throughout	O
radiotherapy	O
.	O

Patients	O
receiving	O
fractionated	O
radiotherapy	I:C1522449
with	O
radiosensitizing	O
chemotherapy	O
received	O
oral	O
ondansetron	B:C0061851
8	O
mg	O
po	O
q12	O
h	O
and	O
aprepitant	O
125/80/80	O
mg	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
Friday	O
schedules	O
throughout	O
radiotherapy	O
.	O

Patients	O
receiving	O
fractionated	O
radiotherapy	I:C1522449
with	O
radiosensitizing	O
chemotherapy	O
received	O
oral	O
ondansetron	O
8	O
mg	O
po	O
q12	O
h	O
and	O
aprepitant	B:C1176306
125/80/80	O
mg	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
Friday	O
schedules	O
throughout	O
radiotherapy	O
.	O

Patients	O
receiving	O
fractionated	O
radiotherapy	I:C1522449
with	O
radiosensitizing	O
chemotherapy	O
received	O
oral	O
ondansetron	O
8	O
mg	O
po	O
q12	O
h	O
and	O
aprepitant	O
125/80/80	O
mg	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
Friday	O
schedules	O
throughout	O
radiotherapy	B:C1522449
.	O

The	O
primary	O
outcome	O
was	O
complete	B:C4050094
response	I:C4050094
(	O
complete	O
response	I:C4050094
)	O
defined	O
as	O
no	O
vomiting	I:C0375548
or	O
rescue	O
therapy	I:C0085405
during	O
the	O
entire	O
observation	O
period	O
of	O
radiotherapy	O
(	O
OP	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
complete	O
response	I:C4050094
(	O
complete	B:C4050094
response	I:C4050094
)	O
defined	O
as	O
no	O
vomiting	I:C0375548
or	O
rescue	O
therapy	I:C0085405
during	O
the	O
entire	O
observation	O
period	O
of	O
radiotherapy	O
(	O
OP	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
complete	O
response	I:C4050094
(	O
complete	O
response	I:C4050094
)	O
defined	O
as	O
no	B:C0375548
vomiting	I:C0375548
or	O
rescue	O
therapy	I:C0085405
during	O
the	O
entire	O
observation	O
period	O
of	O
radiotherapy	O
(	O
OP	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
complete	O
response	I:C4050094
(	O
complete	O
response	I:C4050094
)	O
defined	O
as	O
no	O
vomiting	I:C0375548
or	O
rescue	B:C0085405
therapy	I:C0085405
during	O
the	O
entire	O
observation	O
period	O
of	O
radiotherapy	O
(	O
OP	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
complete	O
response	I:C4050094
(	O
complete	O
response	I:C4050094
)	O
defined	O
as	O
no	O
vomiting	I:C0375548
or	O
rescue	O
therapy	I:C0085405
during	O
the	O
entire	O
observation	B:C0700325
period	O
of	O
radiotherapy	O
(	O
OP	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
complete	O
response	I:C4050094
(	O
complete	O
response	I:C4050094
)	O
defined	O
as	O
no	O
vomiting	I:C0375548
or	O
rescue	O
therapy	I:C0085405
during	O
the	O
entire	O
observation	O
period	O
of	O
radiotherapy	B:C1522449
(	O
OP	O
)	O
.	O

Nausea	B:C0027497
,	O
vomiting	O
,	O
and	O
use	O
of	O
rescue	O
medication	I:C0085405
were	O
recorded	O
in	O
a	O
modified	O
version	O
of	O
the	O
MASCC	O
antiemesis	I:C3714902
tool	I:C3714902
completed	O
twice	O
weekly	O
.	O

Nausea	O
,	O
vomiting	B:C0042963
,	O
and	O
use	O
of	O
rescue	O
medication	I:C0085405
were	O
recorded	O
in	O
a	O
modified	O
version	O
of	O
the	O
MASCC	O
antiemesis	I:C3714902
tool	I:C3714902
completed	O
twice	O
weekly	O
.	O

Nausea	O
,	O
vomiting	O
,	O
and	O
use	O
of	O
rescue	B:C0085405
medication	I:C0085405
were	O
recorded	O
in	O
a	O
modified	O
version	O
of	O
the	O
MASCC	O
antiemesis	I:C3714902
tool	I:C3714902
completed	O
twice	O
weekly	O
.	O

Nausea	O
,	O
vomiting	O
,	O
and	O
use	O
of	O
rescue	O
medication	I:C0085405
were	O
recorded	O
in	O
a	O
modified	O
version	O
of	O
the	O
MASCC	B:C3714902
antiemesis	I:C3714902
tool	I:C3714902
completed	O
twice	O
weekly	O
.	O

57.7	O
%	O
of	O
patients	O
(	O
30/52	O
,	O
95	O
%	O
CI	O
43.2	O
-	O
71.3	O
%	O
)	O
achieved	O
complete	B:C4050094
response	I:C4050094
on	O
study	O
,	O
with	O
73.1	O
%	O
(	O
38/52	O
,	O
95	O
%	O
CI	O
59.0	O
-	O
84.4	O
%	O
)	O
who	O
did	O
not	I:C0375548
vomit	I:C0375548
,	O
and	O
71.2	O
%	O
(	O
37/52	O
,	O
95	O
%	O
CI	O
56.9	O
-	O
82.9	O
%	O
)	O
who	O
did	O
not	O
use	O
rescue	O
medication	I:C0085405
during	O
the	O
OP	O
.	O

57.7	O
%	O
of	O
patients	O
(	O
30/52	O
,	O
95	O
%	O
CI	O
43.2	O
-	O
71.3	O
%	O
)	O
achieved	O
complete	O
response	I:C4050094
on	O
study	B:C2603343
,	O
with	O
73.1	O
%	O
(	O
38/52	O
,	O
95	O
%	O
CI	O
59.0	O
-	O
84.4	O
%	O
)	O
who	O
did	O
not	I:C0375548
vomit	I:C0375548
,	O
and	O
71.2	O
%	O
(	O
37/52	O
,	O
95	O
%	O
CI	O
56.9	O
-	O
82.9	O
%	O
)	O
who	O
did	O
not	O
use	O
rescue	O
medication	I:C0085405
during	O
the	O
OP	O
.	O

57.7	O
%	O
of	O
patients	O
(	O
30/52	O
,	O
95	O
%	O
CI	O
43.2	O
-	O
71.3	O
%	O
)	O
achieved	O
complete	O
response	I:C4050094
on	O
study	O
,	O
with	O
73.1	O
%	O
(	O
38/52	O
,	O
95	O
%	O
CI	O
59.0	O
-	O
84.4	O
%	O
)	O
who	O
did	B:C0375548
not	I:C0375548
vomit	I:C0375548
,	O
and	O
71.2	O
%	O
(	O
37/52	O
,	O
95	O
%	O
CI	O
56.9	O
-	O
82.9	O
%	O
)	O
who	O
did	O
not	O
use	O
rescue	O
medication	I:C0085405
during	O
the	O
OP	O
.	O

57.7	O
%	O
of	O
patients	O
(	O
30/52	O
,	O
95	O
%	O
CI	O
43.2	O
-	O
71.3	O
%	O
)	O
achieved	O
complete	O
response	I:C4050094
on	O
study	O
,	O
with	O
73.1	O
%	O
(	O
38/52	O
,	O
95	O
%	O
CI	O
59.0	O
-	O
84.4	O
%	O
)	O
who	O
did	O
not	I:C0375548
vomit	I:C0375548
,	O
and	O
71.2	O
%	O
(	O
37/52	O
,	O
95	O
%	O
CI	O
56.9	O
-	O
82.9	O
%	O
)	O
who	O
did	O
not	O
use	O
rescue	B:C0085405
medication	I:C0085405
during	O
the	O
OP	O
.	O

Overall	O
,	O
participants	B:C0679646
vomited	O
or	O
experienced	O
significant	O
nausea	I:C0027497
(	O
significant	O
nausea	I:C0027497
)	O
for	O
an	O
average	O
of	O
6.8	O
%	O
(	O
95	O
%	O
CI	O
11.4-21.0	O
)	O
and	O
8.4	O
%	O
(	O
95	O
%	O
CI	O
4.2	O
-	O
12.7	O
%	O
)	O
of	O
time	O
on	O
study	O
,	O
respectively	O
.	O

Overall	O
,	O
participants	O
vomited	B:C0042963
or	O
experienced	O
significant	O
nausea	I:C0027497
(	O
significant	O
nausea	I:C0027497
)	O
for	O
an	O
average	O
of	O
6.8	O
%	O
(	O
95	O
%	O
CI	O
11.4-21.0	O
)	O
and	O
8.4	O
%	O
(	O
95	O
%	O
CI	O
4.2	O
-	O
12.7	O
%	O
)	O
of	O
time	O
on	O
study	O
,	O
respectively	O
.	O

Overall	O
,	O
participants	O
vomited	O
or	O
experienced	O
significant	B:C0027497
nausea	I:C0027497
(	O
significant	O
nausea	I:C0027497
)	O
for	O
an	O
average	O
of	O
6.8	O
%	O
(	O
95	O
%	O
CI	O
11.4-21.0	O
)	O
and	O
8.4	O
%	O
(	O
95	O
%	O
CI	O
4.2	O
-	O
12.7	O
%	O
)	O
of	O
time	O
on	O
study	O
,	O
respectively	O
.	O

Overall	O
,	O
participants	O
vomited	O
or	O
experienced	O
significant	O
nausea	I:C0027497
(	O
significant	B:C0027497
nausea	I:C0027497
)	O
for	O
an	O
average	O
of	O
6.8	O
%	O
(	O
95	O
%	O
CI	O
11.4-21.0	O
)	O
and	O
8.4	O
%	O
(	O
95	O
%	O
CI	O
4.2	O
-	O
12.7	O
%	O
)	O
of	O
time	O
on	O
study	O
,	O
respectively	O
.	O

Overall	O
,	O
participants	O
vomited	O
or	O
experienced	O
significant	O
nausea	I:C0027497
(	O
significant	O
nausea	I:C0027497
)	O
for	O
an	O
average	O
of	O
6.8	O
%	O
(	O
95	O
%	O
CI	O
11.4-21.0	O
)	O
and	O
8.4	O
%	O
(	O
95	O
%	O
CI	O
4.2	O
-	O
12.7	O
%	O
)	O
of	O
time	O
on	O
study	B:C2603343
,	O
respectively	O
.	O

Nausea	B:C0027497
was	O
common	O
with	O
32	O
(	O
61.5	O
%	O
)	O
reporting	O
significant	O
nausea	I:C0027497
at	O
any	O
time	O
during	O
the	O
OP	O
.	O

Nausea	O
was	O
common	O
with	O
32	O
(	O
61.5	O
%	O
)	O
reporting	O
significant	B:C0027497
nausea	I:C0027497
at	O
any	O
time	O
during	O
the	O
OP	O
.	O

UA	B:C1997554
-	I:C1997554
RINV	I:C1997554
remains	O
an	O
important	O
morbidity	O
despite	O
the	O
advent	O
of	O
modern	O
radiotherapy	O
.	O

UA	O
-	I:C1997554
RINV	I:C1997554
remains	O
an	O
important	O
morbidity	O
despite	O
the	O
advent	O
of	O
modern	O
radiotherapy	B:C1522449
.	O

Aprepitant	B:C1176306
and	O
ondansetron	O
as	O
dosed	O
in	O
this	O
trial	O
was	O
not	O
superior	O
to	O
standard	O
ondansetron	O
monotherapy	O
.	O

Aprepitant	O
and	O
ondansetron	B:C0061851
as	O
dosed	O
in	O
this	O
trial	O
was	O
not	O
superior	O
to	O
standard	O
ondansetron	O
monotherapy	O
.	O

Aprepitant	O
and	O
ondansetron	O
as	O
dosed	O
in	O
this	O
trial	B:C0008976
was	O
not	O
superior	O
to	O
standard	O
ondansetron	O
monotherapy	O
.	O

Aprepitant	O
and	O
ondansetron	O
as	O
dosed	O
in	O
this	O
trial	O
was	O
not	O
superior	O
to	O
standard	O
ondansetron	B:C0061851
monotherapy	O
.	O

Aprepitant	O
and	O
ondansetron	O
as	O
dosed	O
in	O
this	O
trial	O
was	O
not	O
superior	O
to	O
standard	O
ondansetron	O
monotherapy	B:C0087111
.	O

